nt miRNA re n in hypo sion in indi ss. (B) Kdm
21
1. Murray, C.J.L. and A.D. Lopez, Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet, 1997.
349(9064): p. 1498-1504.
2. Olvera Lopez, E. and A. Jan, Cardiovascular Disease, in StatPearls. 2018, StatPearls Publishing LLC.: Treasure Island FL.
3. Chatap, G., K. Giraud, and J.-P. Vincent, Atrial fibrillation in the elderly: facts and management. Drugs Aging, 2002. 19(11): p. 819-846.
4. van den Borne, S.W.M., et al., Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol, 2010. 7(1): p. 30-37.
5. Platonov, P.G., Atrial fibrosis: an obligatory component of arrhythmia mechanisms in atrial fibrillation? J Geriatr Cardiol, 2017. 14(4): p. 233-237.
6. Jaffe, I.Z. and M.E. Mendelsohn, Angiotensin II and Aldosterone Regulate Gene Transcription Via Functional Mineralocortocoid Receptors in Human Coronary Artery Smooth Muscle Cells. Circ Res, 2005. 96(6): p. 643-650.
7. Blaxall, B.C., J.M. Miano, and B.C. Berk, Angiotensin II: a devious activator of mineralocorticoid receptor-dependent gene expression. Circ Res, 2005.
96(6): p. 610-611.
8. Chen, J. and J.L. Mehta, Angiotensin II-mediated oxidative stress and procollagen-1 expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone. Am J Physiol Heart Circ Physiol, 2006. 291(4): p.
H1738-H1745.
9. Tsai, C.F., et al., Cross-talk between mineralocorticoid receptor/angiotensin II type 1 receptor and mitogen-activated protein kinase pathways underlies aldosterone-induced atrial fibrotic responses in HL-1 cardiomyocytes. Int J Cardiol, 2013. 169(1): p. 17-28.
10. Kido, M., et al., Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J Am Coll Cardiol, 2005. 46(11): p. 2116-2124.
11. Santos, C.X.C., et al., Redox signaling in cardiac myocytes. Free Radic Biol Med, 2011. 50(7): p. 777-793.
12. Thijssen, V.L.J.L., et al., Analysis of altered gene expression during sustained atrial fibrillation in the goat. Cardiovasc Res, 2002. 54(2): p. 427-437.
13. Gramley, F., et al., Atrial fibrillation is associated with cardiac hypoxia.
Cardiovasc Pathol, 2010. 19(2): p. 102-111.
14. Li, Z., et al., Altered long non-coding RNA expression profile in rabbit atria with atrial fibrillation: TCONS_00075467 modulates atrial electrical remodeling by sponging miR-328 to regulate CACNA1C. J Mol Cell Cardiol, 2017. 108: p. 73-85.
22
15. Viereck, J., et al., Long noncoding RNA Chast promotes cardiac remodeling.
Sci Transl Med, 2016. 8(326): p. 326ra22.
16. Micheletti, R., et al., The long noncoding RNA Wisper controls cardiac fibrosis and remodeling. Sci Transl Med, 2017. 9(395).
17. Wang, W., et al., Transcriptome analysis of canine cardiac fat pads:
involvement of two novel long non-coding RNAs in atrial fibrillation neural remodeling. J Cell Biochem, 2015. 116(5): p. 809-21.
18. Archer, K., et al., Long Non-Coding RNAs as Master Regulators in Cardiovascular Diseases. Int J Mol Sci, 2015. 16(10): p. 23651-67.
19. Ounzain, S. and T. Pedrazzini, The promise of enhancer-associated long noncoding RNAs in cardiac regeneration. Trends Cardiovasc Med, 2015.
25(7): p. 592-602.
20. Ounzain, S. and T. Pedrazzini, Super-enhancer lncs to cardiovascular development and disease. Biochim Biophys Acta, 2016. 1863(7 Pt B): p.
1953-60.
21. Haemmig, S., et al., Long noncoding RNAs in cardiovascular disease, diagnosis, and therapy. Curr Opin Cardiol, 2017. 32(6): p. 776-783.
22. Grimaldi, V., et al., Evidence of epigenetic tags in cardiac fibrosis. J Cardiol, 2017. 69(2): p. 401-408.
23. Huang, S., et al., Long noncoding RNA MALAT1 mediates cardiac fibrosis in experimental postinfarct myocardium mice model. J Cell Physiol, 2019.
234(3): p. 2997-3006.
24. Pugh, C.W. and P.J. Ratcliffe, The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis.
Semin Cancer Biol, 2003. 13(1): p. 83-89.
25. Ockaili, R., et al., HIF-1 activation attenuates postischemic myocardial injury:
role for heme oxygenase-1 in modulating microvascular chemokine generation.
Am J Physiol Heart Circ Physiol, 2005. 289(2): p. H542-H548.
26. Ruan, X., et al., Suxiao Jiuxin Pill protects cardiomyocytes against mitochondrial injury and alters gene expression during ischemic injury. Exp Ther Med, 2017. 14(4): p. 3523-3532.
27. Yu, S.Y., L. Tang, and S.H. Zhou, Long Noncoding RNAs: New Players in Ischaemia-reperfusion Injury. Heart Lung Circ, 2017.
28. Greco, S., et al., Long noncoding RNA dysregulation in ischemic heart failure.
J Transl Med, 2016. 14(1): p. 183.
29. Yang, L. and Z.N. Lu, Long non-coding RNA HOTAIR promotes ischemic infarct induced by hypoxia through up-regulating the expression of NOX2.
Biochem Biophys Res Commun, 2016. 479(2): p. 186-191.
23
30. Heeneman, S., et al., The dynamic extracellular matrix: intervention strategies during heart failure and atherosclerosis. J Pathol, 2003. 200(4): p. 516-525.
31. Lu, Y.Y., et al., Collagen regulates transforming growth factor-beta receptors of HL-1 cardiomyocytes through activation of stretch and integrin signaling.
Mol Med Rep, 2016. 14(4): p. 3429-36.
32. Oka, T. and I. Komuro, Molecular mechanisms underlying the transition of cardiac hypertrophy to heart failure. Circ J, 2008. 72(SupplementA): p.
A13-A16.
33. Miner, E.C. and W.L. Miller, A look between the cardiomyocytes: the extracellular matrix in heart failure. Mayo Clin Proc, 2006. 81(1): p. 71-76.
34. Parkes, J.G., et al., Changes in gene expression with iron loading and chelation in cardiac myocytes and non-myocytic fibroblasts. J Mol Cell Cardiol, 2000.
32(2): p. 233-246.
35. Rude, M.K., et al., Aldosterone stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes. Hypertension, 2005. 46(3): p. 555-561.
36. Madani, S., et al., Direct effects of leptin on size and extracellular matrix components of human pediatric ventricular myocytes. Cardiovasc Res, 2006.
69(3): p. 716-725.
37. Care, A., et al., MicroRNA-133 controls cardiac hypertrophy. Nat Med, 2007.
13(5): p. 613-8.
38. Greco, S., et al., Long Noncoding RNAs and Cardiac Disease. Antioxid Redox Signal, 2017.
39. Rinn, J.L., et al., Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell, 2007. 129(7): p.
1311-23.
40. Pandey, R.R., et al., Kcnq1ot1 antisense noncoding RNA mediates lineage-specific transcriptional silencing through chromatin-level regulation.
Mol Cell, 2008. 32(2): p. 232-46.
41. Klattenhoff, C.A., et al., Braveheart, a long noncoding RNA required for cardiovascular lineage commitment. Cell, 2013. 152(3): p. 570-83.
42. Greenberg, B., et al., Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet, 2016.
387(10024): p. 1178-86.
43. Wang, X., et al., Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription. Nature, 2008. 454(7200): p. 126-30.
44. Feng, J., et al., The Evf-2 noncoding RNA is transcribed from the Dlx-5/6
24
ultraconserved region and functions as a Dlx-2 transcriptional coactivator.
Genes Dev, 2006. 20(11): p. 1470-84.
45. Martianov, I., et al., Repression of the human dihydrofolate reductase gene by a non-coding interfering transcript. Nature, 2007. 445(7128): p. 666-70.
46. Beltran, M., et al., A natural antisense transcript regulates Zeb2/Sip1 gene expression during Snail1-induced epithelial-mesenchymal transition. Genes Dev, 2008. 22(6): p. 756-69.
47. Shi, X., et al., Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett, 2013. 339(2): p. 159-66.
48. Swiezewski, S., et al., Cold-induced silencing by long antisense transcripts of an Arabidopsis Polycomb target. Nature, 2009. 462(7274): p. 799-802.
49. Houseley, J., et al., A ncRNA modulates histone modification and mRNA induction in the yeast GAL gene cluster. Mol Cell, 2008. 32(5): p. 685-95.
50. Ma, L., V.B. Bajic, and Z. Zhang, On the classification of long non-coding RNAs. RNA Biol, 2013. 10(6): p. 925-33.
51. Novikova, I.V., S.P. Hennelly, and K.Y. Sanbonmatsu, Sizing up long non-coding RNAs: do lncRNAs have secondary and tertiary structure?
Bioarchitecture, 2012. 2(6): p. 189-99.
52. Lee, C. and N. Kikyo, Strategies to identify long noncoding RNAs involved in gene regulation. Cell Biosci, 2012. 2(1): p. 37.
53. Batista, P.J. and H.Y. Chang, Long noncoding RNAs: cellular address codes in development and disease. Cell, 2013. 152(6): p. 1298-307.
54. Long, Y., et al., How do lncRNAs regulate transcription? Sci Adv, 2017. 3(9):
p. eaao2110.
55. Yang, K.C., et al., Deep RNA sequencing reveals dynamic regulation of myocardial noncoding RNAs in failing human heart and remodeling with mechanical circulatory support. Circulation, 2014. 129(9): p. 1009-21.
56. Mas-Ponte, D., et al., LncATLAS database for subcellular localization of long noncoding RNAs. RNA, 2017. 23(7): p. 1080-1087.
57. You, B.H., S.H. Yoon, and J.W. Nam, High-confidence coding and noncoding transcriptome maps. Genome Res, 2017. 27(6): p. 1050-1062.
58. Saleembhasha, A. and S. Mishra, Novel molecules lncRNAs, tRFs and circRNAs deciphered from next-generation sequencing/RNA sequencing:
computational databases and tools. Brief Funct Genomics, 2017.
59. Lucas, T., A. Bonauer, and S. Dimmeler, RNA Therapeutics in Cardiovascular Disease. Circ Res, 2018. 123(2): p. 205-220.
60. Yoon, J.H., K. Abdelmohsen, and M. Gorospe, Posttranscriptional gene regulation by long noncoding RNA. J Mol Biol, 2013. 425(19): p. 3723-30.
25
61. Devaux, Y., et al., Long noncoding RNAs in cardiac development and ageing.
Nat Rev Cardiol, 2015. 12(7): p. 415-25.
62. Huang, Z.P., et al., Long non-coding RNAs link extracellular matrix gene expression to ischemic cardiomyopathy. Cardiovasc Res, 2016.
63. Qu, X., et al., Expression signature of lncRNAs and their potential roles in cardiac fibrosis of post-infarct mice. Biosci Rep, 2016. 36(3).
64. Gao, J., et al., The Role and Molecular Mechanism of Non-Coding RNAs in Pathological Cardiac Remodeling. Int J Mol Sci, 2017. 18(3).
65. Shen, S., et al., Long Non-Coding RNAs in Cardiac Remodeling. Cell Physiol Biochem, 2017. 41(5): p. 1830-1837.
66. Wang, K., et al., The long noncoding RNA NRF regulates programmed necrosis and myocardial injury during ischemia and reperfusion by targeting miR-873. Cell Death Differ, 2016. 23(8): p. 1394-405.
67. Leisegang, M.S., LET's sponge: How the lncRNA PFL promotes cardiac fibrosis. Theranostics, 2018. 8(4): p. 874-877.
68. Wang, K., et al., APF lncRNA regulates autophagy and myocardial infarction by targeting miR-188-3p. Nat Commun, 2015. 6: p. 6779.
69. Zhao, Z.H., et al., Long non-coding RNA MALAT1 functions as a mediator in cardioprotective effects of fentanyl in myocardial ischemia-reperfusion injury.
Cell Biol Int, 2017. 41(1): p. 62-70.
70. Wang, J.X., et al., MicroRNA-103/107 Regulate Programmed Necrosis and Myocardial Ischemia/Reperfusion Injury Through Targeting FADD. Circ Res, 2015. 117(4): p. 352-63.
71. Wang, J., et al., MicroRNA-24 regulates cardiac fibrosis after myocardial infarction. J Cell Mol Med, 2012. 16(9): p. 2150-60.
72. Jiang, F., X. Zhou, and J. Huang, Long Non-Coding RNA-ROR Mediates the Reprogramming in Cardiac Hypertrophy. PLoS One, 2016. 11(4): p.
e0152767.
73. Zhu, X.H., et al., LncRNA MIAT enhances cardiac hypertrophy partly through sponging miR-150. Eur Rev Med Pharmacol Sci, 2016. 20(17): p. 3653-60.
74. Qu, X., et al., MIAT Is a Pro-fibrotic Long Non-coding RNA Governing Cardiac Fibrosis in Post-infarct Myocardium. Sci Rep, 2017. 7: p. 42657.
75. Chaudary, N., et al., Transport characteristics of HL-1 cells: a new model for the study of adenosine physiology in cardiomyocytes. Biochem Cell Biol, 2002. 80(5): p. 655-665.
76. White, S.M., P.E. Constantin, and W.C. Claycomb, Cardiac physiology at the cellular level: use of cultured HL-1 cardiomyocytes for studies of cardiac muscle cell structure and function. Am J Physiol Heart Circ Physiol, 2004.
26
286(3): p. H823-H829.
77. Eimre, M., et al., Distinct organization of energy metabolism in HL-1 cardiac cell line and cardiomyocytes. Biochim Biophys Acta, 2008. 1777(6): p.
514-524.
78. Ikeda, K., et al., 5-Hydroxytryptamine synthesis in HL-1 cells and neonatal rat cardiocytes. Biochem Biophys Res Commun, 2005. 328(2): p. 522-525.
79. Tsai, C.-T., et al., Renin-angiotensin system component expression in the HL-1 atrial cell line and in a pig model of atrial fibrillation. J Hypertens, 2008.
26(3): p. 570-582
80. Nguyen, S.V. and W.C. Claycomb, Hypoxia regulates the expression of the adrenomedullin and HIF-1 genes in cultured HL-1 cardiomyocytes. Biochem Biophys Res Commun, 1999. 265(2): p. 382-386.
81. Chaudary, N., et al., Hypoxia regulates the adenosine transporter, mENT1, in the murine cardiomyocyte cell line, HL-1. Cardiovasc Res 2004. 61(4): p.
780-788.
82. Robador, P.A., et al., HIF-1 mediated up-regulation of cardiotrophin-1 is involved in the survival response of cardiomyocytes to hypoxia. Cardiovasc Res, 2011. 92(2): p. 247-55.
83. Yu, F., et al., NEAT1 accelerates the progression of liver fibrosis via regulation of microRNA-122 and Kruppel-like factor 6. J Mol Med (Berl), 2017. 95(11): p. 1191-1202.
84. Kesherwani, V., H.R. Shahshahan, and P.K. Mishra, Cardiac transcriptome profiling of diabetic Akita mice using microarray and next generation sequencing. PLoS One, 2017. 12(8): p. e0182828.
85. Tao, H., et al., LncRNA GAS5 controls cardiac fibroblast activation and fibrosis by targeting miR-21 via PTEN/MMP-2 signaling pathway.
Toxicology, 2017. 386: p. 11-18.
86. Testoni, S., et al., KDM2B is implicated in bovine lethal multi-organic developmental dysplasia. PLoS One, 2012. 7(9): p. e45634.
87. Batrakou, D.G., et al., TMEM120A and B: Nuclear Envelope Transmembrane Proteins Important for Adipocyte Differentiation. PLoS ONE, 2015. 10(5): p.
e0127712.
88. El Agha, E., et al., Two-Way Conversion between Lipogenic and Myogenic Fibroblastic Phenotypes Marks the Progression and Resolution of Lung Fibrosis. Cell Stem Cell, 2017. 20(4): p. 571.
89. Fang, F., et al., A synthetic TLR3 ligand mitigates profibrotic fibroblast responses by inducing autocrine IFN signaling. J Immunol, 2013. 191(6): p.
2956-66.
27
90. Li, Y., et al., Cardiac Fibroblast-Specific Activating Transcription Factor 3 Protects Against Heart Failure by Suppressing MAP2K3-p38 Signaling.
Circulation, 2017. 135(21): p. 2041-2057.
91. Calvo, F., et al., Cdc42EP3/BORG2 and Septin Network Enables Mechano-transduction and the Emergence of Cancer-Associated Fibroblasts.
Cell Reports, 2015. 13(12): p. 2699-2714.
92. Todorovic, V. and D.B. Rifkin, LTBPs, more than just an escort service. J Cell Biochem, 2012. 113(2): p. 410-8.
93. Hinz, B., The extracellular matrix and transforming growth factor-β1: Tale of a strained relationship. Matrix Biology, 2015. 47(Supplement C): p. 54-65.